Baird raised the firm’s price target on Climb Bio (CLYM) to $21 from $12 and keeps an Outperform rating on the shares. The firm updated its model following its R&D event which highlighted the broad potential for CD19.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: